Pfizer successfully defends Norvasc patent against Mylan

Share this article:
A federal court in the Western District of Pennsylvania (Pittsburgh) has upheld Pfizer’s patent covering the active ingredient in its blockbuster hypertension drug Norvasc. The patent had been challenged by generic manufacturer Mylan. Judge Terrence McVerry ruled the patent covering Norvasc’s active ingredient, amlodipine besylate, is valid, enforceable and would be infringed by Mylan’s product. The decision, which is subject to appeal, prohibits Mylan from launching a generic version of Norvasc until Sept. 25, 2007. Mylan issued a statement saying that it disagrees with the court’s decision and would immediately appeal the ruling. Pfizer previously defeated challenges to the same patent brought by two other generic drug makers. In January 2006, a federal court in the Northern District of Illinois ruled against Canadian generic manufacturer Apotex. In August 2006, a federal court in the Middle District of North Carolina rejected a challenge by Dutch generic manufacturer Synthon. Both of those decisions have been appealed. Norvasc had annual US sales of $2.5 billion during 2006. Although the main patent on Norvasc will expire next month, the FDA has granted six months of pediatric exclusivity for Norvasc. When Mylan finally is able to launch its generic version of Norvasc, it will have 180 days of marketing exclusivity as the first abbreviated new drug application filer.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...